JP2007519618A - グルコキナーゼ（ｇｌｋ）活性化剤として有用なベンゾイルアミノピリジルカルボン酸誘導体 - Google Patents

グルコキナーゼ（ｇｌｋ）活性化剤として有用なベンゾイルアミノピリジルカルボン酸誘導体 Download PDF

Info

Publication number
JP2007519618A
JP2007519618A JP2006542008A JP2006542008A JP2007519618A JP 2007519618 A JP2007519618 A JP 2007519618A JP 2006542008 A JP2006542008 A JP 2006542008A JP 2006542008 A JP2006542008 A JP 2006542008A JP 2007519618 A JP2007519618 A JP 2007519618A
Authority
JP
Japan
Prior art keywords
compound
formula
salt
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006542008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519618A5 (enExample
Inventor
コールケット，ピーター・ウィリアム・ロドニー
ジョンストーン，クレイグ
マッケレッチャー，ダーレン
パイク，カート・ゴードン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007519618A publication Critical patent/JP2007519618A/ja
Publication of JP2007519618A5 publication Critical patent/JP2007519618A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2006542008A 2003-12-05 2004-12-02 グルコキナーゼ（ｇｌｋ）活性化剤として有用なベンゾイルアミノピリジルカルボン酸誘導体 Withdrawn JP2007519618A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328178.9A GB0328178D0 (en) 2003-12-05 2003-12-05 Compounds
PCT/GB2004/005068 WO2005056530A1 (en) 2003-12-05 2004-12-02 Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators

Publications (2)

Publication Number Publication Date
JP2007519618A true JP2007519618A (ja) 2007-07-19
JP2007519618A5 JP2007519618A5 (enExample) 2007-09-27

Family

ID=29764609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006542008A Withdrawn JP2007519618A (ja) 2003-12-05 2004-12-02 グルコキナーゼ（ｇｌｋ）活性化剤として有用なベンゾイルアミノピリジルカルボン酸誘導体

Country Status (6)

Country Link
US (1) US20090062351A1 (enExample)
EP (1) EP1697325A1 (enExample)
JP (1) JP2007519618A (enExample)
CN (1) CN1890219A (enExample)
GB (1) GB0328178D0 (enExample)
WO (1) WO2005056530A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536773A (ja) * 2007-08-13 2010-12-02 リガンド・ファーマシューティカルズ・インコーポレイテッド グルコキナーゼの新規な活性化剤

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1718624B1 (en) * 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CN101437512A (zh) * 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
GEP20135783B (en) * 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
JP2011529955A (ja) 2008-08-04 2011-12-15 アストラゼネカ アクチボラグ 治療薬４１４
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2020037109A1 (en) * 2018-08-17 2020-02-20 Dow Agrosciences Llc Processes for fluorination

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536773A (ja) * 2007-08-13 2010-12-02 リガンド・ファーマシューティカルズ・インコーポレイテッド グルコキナーゼの新規な活性化剤
US8940927B2 (en) 2007-08-13 2015-01-27 Metabasis Therapeutics, Inc. Activators of glucokinase
US9522926B2 (en) 2007-08-13 2016-12-20 Metabasis Therapeutics, Inc. Activators of glucokinase
US10174062B2 (en) 2007-08-13 2019-01-08 Metabasis Therapeutics, Inc. Activators of glucokinase

Also Published As

Publication number Publication date
EP1697325A1 (en) 2006-09-06
GB0328178D0 (en) 2004-01-07
WO2005056530A1 (en) 2005-06-23
US20090062351A1 (en) 2009-03-05
CN1890219A (zh) 2007-01-03

Similar Documents

Publication Publication Date Title
JP2007519618A (ja) グルコキナーゼ（ｇｌｋ）活性化剤として有用なベンゾイルアミノピリジルカルボン酸誘導体
US20070078168A1 (en) Pyridine carboxylic acid derivatives as glucokinase modulators
US20070255062A1 (en) Benzoyl Amino Pyridyl Carboxylic Acid Derivatives Useful as Glucokinase (Glk) Activators
US7199140B2 (en) Vinyl phenyl derivatives as GLK activators
JP2007512300A (ja) グルコキナーゼ活性化剤としてのベンゾイルアミノピリジルカルボン酸誘導体
RU2440992C2 (ru) Бензоиламиногетероциклильные соединения в качестве активаторов глюкокиназы (glk)
EP1578745B1 (en) BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF
US20040214868A1 (en) Amino nicotinate derivatives as glucokinase (GLK) modulators
JP2007523905A (ja) 化合物
JP2009500442A (ja) ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
US20080280874A1 (en) Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity
JP2009500444A (ja) 糖尿病の治療においてｇｌｋアクチベータとして使用するためのヘテロアリールベンズアミド誘導体
US20070287693A1 (en) Benzamide Derivatives That Act Upon The Glucokinase Enzyme
HK1092803B (en) Benzoyl amino pyridyl carboxylic acid derivatives as glucokinase activators
MXPA06004779A (en) Pyridine carboxylic acid derivatives as glucokinase modulators
CN101568534A (zh) 用于治疗glk介导的疾病的苯甲酰基氨基杂环化合物
HK1062888B (en) Vinyl phenyl derivatives as glk activators
HK1116769A1 (en) Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
HK1116769B (en) Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
HK1149552A (en) Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070808

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080918